文献速递儿童青少年精神

成人注意缺陷多动障碍的许可与超许可剂量兴奋剂治疗结局:系统综述与Meta分析

Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该系统综述与Meta分析纳入47项双盲随机对照试验(7714例成人ADHD患者),评估兴奋剂剂量与治疗结局的关系。基于群体平均,超许可剂量相比许可剂量在哌甲酯中症状改善额外获益很小且不良事件停药风险增加,在安非他命中未见症状额外改善但不良事件停药风险持续增加。结论提示超许可剂量可能不具有正向风险获益,临床应谨慎考虑。

要点

  • 超许可剂量哌甲酯症状改善额外获益很小(SMD -0.23),但不良事件停药风险增加(OR 2.02)。
  • 安非他命剂量-反应曲线接近平台,增量不额外改善症状但不良事件停药风险持续增加。
  • 基于群体平均,超许可剂量相比许可剂量可能不具有正向风险获益,临床应谨慎使用。

核心结论

  • 基于群体平均,成人ADHD超许可剂量兴奋剂相比许可剂量可能不具有正向风险获益。
  • 临床医生应谨慎考虑超许可剂量,必要时可试用但需知晓进一步增量可能无大幅疗效增益。
  • 研究结果为平均值,不能推广至每一位患者。

研究设计与样本

  • 纳入47项双盲随机对照试验,共7714例成人(18岁及以上)ADHD患者,平均年龄35岁(SD 11),男性4204例(56%)。
  • 采用随机效应剂量-反应Meta分析和网络Meta分析合成聚合数据。

主要发现

  • 哌甲酯剂量-反应曲线显示剂量增加症状进一步减轻,但增益逐渐变小且不良事件停药风险持续增加。
  • 网络Meta分析显示超许可剂量哌甲酯相比许可剂量症状减轻更多(SMD -0.23;95% CI -0.44至-0.02;证据确定性极低),但额外增益小且不良事件停药风险增加(OR 2.02;95% CI 1.19-3.43;证据确定性中等)。
  • 安非他命剂量-反应曲线接近平台,剂量增量未显示症状进一步减轻,但不良事件停药风险持续增加。
  • 网络Meta分析未发现安非他命超许可与许可剂量在症状减轻上有差异(SMD -0.08;95% CI -0.24至0.08;证据确定性极低)。

关键数值与推荐

  • 主要结局为ADHD症状变化和因不良事件停药。
  • 哌甲酯超许可vs许可剂量:症状SMD -0.23(95% CI -0.44至-0.02),不良事件停药OR 2.02(95% CI 1.19-3.43)。
  • 安非他命超许可vs许可剂量:症状SMD -0.08(95% CI -0.24至0.08)。

临床怎么用

  • 基于群体平均,临床医生应谨慎考虑成人ADHD的超许可剂量兴奋剂处方。
  • 必要时可试用超许可剂量若患者需要且耐受,但应知晓进一步剂量增量可能无大幅疗效增益。
  • 研究结果为平均值,不能推广至每一位患者,需个体化评估。

局限性

  • 证据确定性极低至中等,尤其超许可剂量比较的症状结局证据确定性极低。
  • 结果为群体平均值,不能推广至每一位患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stimulants (methylphenidate and amphetamines) are often prescribed at unlicensed doses for adults with attention-deficit/hyperactivity disorder (ADHD). Whether dose escalation beyond US Food and Drug Administration recommendations is associated with positive risk benefits is unclear. OBJECTIVE: To investigate the impact, based on averages, of stimulant doses on treatment outcomes in adults with ADHD and to determine, based on averages, whether unlicensed doses are associated with positive risk benefits compared with licensed doses. DATA SOURCES: Twelve databases, including published (PubMed, Cochrane Library, Embase, Web of Sciences) and unpublished (ClinicalTrials.gov) literature, up to February 22, 2023, without language restrictions. STUDY SELECTION: Two researchers independently screened records to identify double-blinded randomized clinical trials of stimulants against placebo in adults (18 years and older) with ADHD. DATA EXTRACTION AND SYNTHESIS: Aggregate data were extracted and synthesized in random-effects dose-response meta-analyses and network meta-analyses. MAIN OUTCOME MEASURES: Change in ADHD symptoms and discontinuations due to adverse events. RESULTS: A total of 47 randomized clinical trials (7714 participants; mean age, 35 (SD, 11) years; 4204 male [56%]) were included. For methylphenidate, dose-response curves indicated additional reductions of symptoms with increments in doses, but the gains were progressively smaller and accompanied by continued additional risk of adverse events dropouts. Network meta-analyses showed that unlicensed doses were associated with greater reductions of symptoms compared with licensed doses (standardized mean difference [SMD], -0.23; 95% CI, -0.44 to -0.02; very low certainty of evidence), but the additional gain was small and accompanied by increased risk of adverse event dropouts (odds ratio, 2.02; 95% CI, 1.19-3.43; moderate certainty of evidence). For amphetamines, the dose-response curve approached a plateau and increments in doses did not indicate additional reductions of symptoms, but there were continued increments in the risk of adverse event dropouts. Network meta-analysis did not identify differences between unlicensed and licensed doses for reductions of symptoms (SMD, -0.08; 95% CI, -0.24 to 0.08; very low certainty of evidence). CONCLUSIONS AND RELEVANCE: Based on group averages, unlicensed doses of stimulants may not have positive risk benefits compared with licensed doses for adults with ADHD. In general, practitioners should consider unlicensed doses cautiously. Practitioners may trial unlicensed doses if needed and tolerated but should be aware that there may not be large gains in the response to the medication with those further increments in dose. However, the findings are averages and will not generalize to every patient.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Farhat LC, Flores JM, Avila-Quintero VJ, et al. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024. PMID: 37878348. doi:10.1001/jamapsychiatry.2023.3985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。